COA in the News

February 24: NCPA Lobbies Hard For Bill Banning Retroactive Pharmacy Concessions

The National Community Pharmacists Association is lobbying hard for recently reintroduced legislation that would prohibit retroactive pharmacy concessions, and believes the bill has a better chance of passage this year in the wake of a new CMS report on the [...]

February 23: Integrating Patient-Centered Outcomes in APMs

HEALTH PLANS ARE INCREASINGLY CREATING contracts with providers that tie the quality of care to payment decisions, a trend that has already made its mark in oncology with bundled and episodic payments. While most find it difficult to move away [...]

February 17: PBMs and DIR Fees: Where’s the Data?

Direct and indirect remuneration (DIR) fees are an issue that has caused outrage among a majority of pharmacy providers. These fees are charged by pharmacy benefit managers (PBMs) to pharmacies who operate within the network months after the initial transaction. [...]

February 17: From Bench to Community Oncology Clinic: The Promise of Immunotherapy

Immunotherapy as a treatment modality for cancer has been studied for over 5 decades. However, with the recent surge in new treatment options, immunotherapy seems to have come of age. An increasing number of immunotherapy agents have been approved for [...]

February 17: Congress Reintroduces DIR Fee Legislation

Reps. Morgan Griffith (R., Va.) and Peter Welch (D., Vt.) have reintroduced the Improving Transparency and Accuracy in Medicare Part D Spending Act (H.R. 1038), which community pharmacies say would squelch a growing burden: retroactive direct and indirect remuneration (DIR) fees. [...]

February 13: COA Applauds Confirmation of Dr. Tom Price as HHS Secretary

On behalf of the Board of Directors of the Community Oncology Alliance (COA), I want to express our support for Dr. Tom Price as Secretary of Health and Human Services (HHS). Read the full article on Newswise here.

February 9: Community Oncology Alliance State of Community Oncology and 2017 Priorities

Today, the Community Oncology Alliance (COA) hosted a "State of the Union" briefing on the state of community oncology at the National Press Club in Washington, DC. More than 100 representatives of national cancer care, patient advocacy, provider, and industry [...]

February 9: How to Start Lowering Drug Prices Now

President Donald Trump took an important step in the right direction when he recently met with pharmaceutical executives and expressed grave concern about high drug prices. Escalating prices, especially for life-saving cancer therapies, are a serious problem for patients that [...]

February 7: Study: DIR Fees Harmful to All Except PBMs

Recently, pharmacy benefit managers (PBMs) have begun charging providers direct and indirect remuneration fees (DIR fees), which has resulted in many specialty pharmacies and physician-run practices closing their doors or increasing costs. Read the full article on Specialty Pharmacy Times [...]

February 6: Report Commissioned by COA Explores “Murky” World of Pharmacy DIR Fees

A white paper commissioned by the Community Oncology Alliance (COA) delved into the practice of “direct and indirect remuneration” (DIR) fees administered by pharmacy benefit managers (PBMs) and how they could drive up drug prices for Medicare Part D beneficiaries [...]


Formal Comments on Medicare Part B Experiment

It is an Experiment that is Bad Medicine, Flawed Economics, Destructive Policy, and Legally Invalid...

Fact Check Report on Medicare Part B Experiment Concerns

Flawed Analysis: Fact-Checking the MSK Evidence Driven Drug Pricing Project Review of Congressional Concerns Regarding the Medicare Part B Drug Payment Model

A Video from Joan Lunden

A Conversation with Joan Lunden On Community Oncology